Loading, Please Wait...
SAN DIEGO, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN) announces the first commercial use of the Obalon Navigation System™ and Touch™ Inflation Dispenser for balloon administration. The Obalon Navigation System and Touch Inflation Dispenser are intended to improve the reliability and ease of balloon administration, and to reduce the costs and logistics for physicians to adopt the Obalon Balloon System as a non-surgical treatment for their patients with obesity.
Dr. Shawn Garber of New York Bariatric Group, who performed the first commercial administration using the Obalon Navigation System said, “We have made the Obalon Balloon a standard of care in my practice with outstanding outcomes for patients. The new Obalon Navigation System, which eliminates the need for x-ray, improves the ease of use and will allow us to now more easily and economically treat patients with systems at multiple sites.”
Kelly Huang, PhD, CEO of Obalon added, “We believe the Obalon Navigation System addresses the largest barrier for physician adoption and will allow us to further penetrate the significant potential market for patients with obesity. We remain dedicated to helping obese adults with a body mass index (BMI) of between 30 and 40 kg/m2 achieve effective weight loss to improve their health and increase their self-esteem.”
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. For more information, please visit www.obalon.com.
To the extent that statements contained in this press release are not descriptions of historical facts regarding Obalon Therapeutics, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause Obalon Therapeutics' future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the product research, development and regulatory process and risks. Obalon Therapeutics undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Obalon Therapeutics' business in general, please refer to Obalon Therapeutics’ annual report on Form 10-K filed with the Securities and Exchange Commission on February 22, 2019, and its current and future periodic reports filed with the Securities and Exchange Commission.
For Obalon Therapeutics, Inc.
Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103